Continuous melt-spinning of 95:5 L-lactide/ε-caprolactone copolymer with an inherent viscosity midpoint of 1.7 dL/g begins with vacuum drying at 60 °C and 10 mbar until residual moisture remains below 250 ppm. A single-screw extruder with 24:1 L/D and a 1.0 mm diameter capillary die is configured with barrel set points of 170 °C, 185 °C, 195 °C, and 200 °C from feed to metering zone. Melt pressure is maintained below 80 bar to limit chain scission from viscous heating. The extrudate is quenched in a water bath at 25 °C and drawn over a heated godet pair at 60 °C to a total draw ratio between 4:1 and 6:1. Fiber tensile testing is performed per ASTM D2256/D2256M-21 after conditioning at 23 °C and 50% RH for 48 h. A residual caprolactone-rich amorphous phase lowers the modulus and reduces brittle fracture during knotting compared with pure PLLA of equivalent molecular weight. Batch-to-batch variation in inherent viscosity between 1.5 dL/g and 1.9 dL/g requires draw-ratio adjustment of approximately 0.5 per 0.2 dL/g increase to avoid draw resonance. In vitro degradation of the drawn fiber is assessed in phosphate-buffered saline at 37 °C and pH 7.4 according to ASTM F1635-16. Molecular weight retention is tracked by size-exclusion chromatography per ISO 16014-1. The usefulness of this exact grade for marketed monofilament wound-closure devices is not established by the raw-material certificate; final product biological testing under ISO 10993-1, ISO 10993-5, and ISO 10993-10 remains mandatory.

What Limits Injection Molding Cycle Time for Craniofacial Fixation Plates?

Injection molding of thin-wall craniofacial plates from this copolymer is constrained by the narrow temperature corridor between complete plastication and accelerated random chain scission above 210 °C. Mold temperatures between 20 °C and 40 °C are selected to promote surface crystallization of L-lactide segments while avoiding premature part sticking. For a four-cavity plate tool with a flow length of 80 mm and wall thickness of 1.5 mm, mold-flow calculations typically indicate clamping force in the 250–350 t range. Screw rotation speed is held between 60 rpm and 120 rpm, with back pressure near 10 bar and injection pressure up to 1,200 bar. The granules must be dried to below 250 ppm moisture before hopper feeding; moisture-induced hydrolysis during plastication causes measurable molecular-weight reduction and melt-flow-index shift that alters cavity filling. Post-molding annealing at 110 °C for 4 h under vacuum increases dimensional stability. Green-state and post-anneal shrinkage are compared using a coordinate measuring machine. Tensile and flexural data are generated per ISO 527-2 and ISO 178:2019. Degradation rate is measured by ISO 13781:2017, which requires documenting mass loss, molecular weight, and mechanical property retention over time. Device-specific biological evaluation is performed under ISO 10993-3, ISO 10993-5, and ISO 10993-6. Because residual catalyst and lactide monomer levels are batch-specific, processing at the upper end of the melt-temperature range must be accompanied by post-run residual-monomer verification. Published data for this specific grade in craniofacial plate tools is limited; mold-flow simulation input should be validated against in-house rheology data rather than generic PLGA databases.

Electrospinning of 95:5 L-lactide/ε-caprolactone copolymer from a chloroform/acetone binary solvent at 12 wt% solids produces fiber diameters between 0.5 µm and 2.0 µm when the applied voltage is 18 kV and the spinneret-to-collector distance is 15 cm. A rotating mandrel at 1,200 rpm is used to orient fibers circumferentially for vascular graft constructs. Residual solvent removal is performed by vacuum drying at 40 °C for 48 h; headspace gas chromatography is then used to verify residual chloroform below 50 ppm before cell-contact assays. Radial dynamic compliance is evaluated under cyclic pressure from 80 mmHg to 120 mmHg according to ISO 7198:2016. Suture retention strength is measured with a 5-0 polypropylene suture inserted 2.0 mm from the scaffold edge and pulled at 10 mm/min. The crystalline lactide-rich domains contribute temporary mechanical integrity while the ε-caprolactone-rich amorphous regions lower flexural stiffness relative to pure PLLA. In vitro degradation is tracked per ASTM F1635-16 in 0.01 M phosphate-buffered saline at 37 °C. Batch consistency in fiber diameter depends on ambient relative humidity; electrospinning at relative humidity above 60% RH can produce surface porosity that changes the effective degradation surface area. Published data for this specific high-viscosity grade in FDA-cleared vascular scaffolds is limited; final device evaluation under ISO 10993-4 and ISO 10993-6 is required.

Solvent-Cast Coatings for Drug-Eluting Implant Surfaces

Thin films are prepared by dissolving the copolymer in dichloromethane or chloroform at 1.0–2.5 wt% solids. The solution is filtered through 0.2 µm PTFE and applied by ultrasonic spray coating or precision dip coating onto metallic or polymeric implant substrates. Drying at 23 °C for 12 h followed by vacuum at 40 °C for 24 h reduces residual solvent below 35 ppm as verified by headspace GC per USP <467>. Coating thickness is controlled between 5 µm and 20 µm by adjusting withdrawal speed from 10 mm/s to 50 mm/s in dip coating or by pass count in ultrasonic spraying. The high L-lactide content produces a semi-crystalline coating that resists delamination during crimping on balloon-expandable stents, while the caprolactone-rich phase lowers the crack-propagation rate. Release kinetics from the matrix are governed by water uptake, plasticization, and hydrolytic ester cleavage; the 95:5 lactide-to-caprolactone ratio yields slower degradation than amorphous 50:50 PLGA coatings. Leachables and degradation products should be assessed under ISO 10993-13 and ISO 10993-17:2023. Coating integrity after crimping and expansion is evaluated by scanning electron microscopy and mechanical testing per ISO 7198:2016 where stent-graft requirements apply. The use of this specific grade in commercial drug-eluting stents is not confirmed by the raw-material datasheet; device-specific coating formulation and toxicological risk assessment are mandatory.

Before fused filament fabrication of patient-specific scaffolds begins, the copolymer is extruded into 1.75 mm diameter filament at 180 °C. A laser micrometer controls diameter tolerance within ±0.05 mm. Printing proceeds with a hardened steel nozzle at 195–205 °C, a build plate at 45 °C, and a layer height of 0.15 mm. Print speed is maintained below 40 mm/s to avoid interlayer fusion defects at the deposition boundary. Printed scaffolds are annealed at 100 °C for 6 h under vacuum to relieve residual stress and stabilize crystallinity. Mechanical anisotropy is assessed by tensile testing of specimens printed at 0°, 45°, and 90° raster orientations per ASTM D638-14. Dimensional accuracy is compared to the reference CAD geometry by optical scanning. In vitro degradation is measured per ASTM F1635-16 in 0.01 M phosphate-buffered saline at 37 °C. Because the high inherent viscosity of this grade reduces melt interdiffusion, layer adhesion may be lower than that of lower-molecular-weight PLCL grades unless print parameters are optimized. Published data for this specific grade in FDA-cleared printed implants is limited; material-process validation under ISO 13485 and final device biological evaluation under ISO 10993-5 and ISO 10993-6 are required.

When Annealing Must Be Validated for Load-Bearing Device Geometry

When the copolymer is used in load-bearing bioabsorbable screws or osteochondral fixation devices, post-mold annealing is necessary to increase crystallinity and reduce creep under sustained compression at 37 °C. Annealing protocols at 105–115 °C for 4–12 h are executed under vacuum or nitrogen because oxidative degradation of the caprolactone-containing segments can occur at elevated temperature in air. Differential scanning calorimetry per ISO 11357-1:2023 typically shows a glass transition near 55–60 °C and a broad melt endotherm in the 150–165 °C range for 95:5 copolymers of this viscosity class. The annealed device must be tested for molecular weight retention by size-exclusion chromatography per ISO 16014-1. Torque and pull-out resistance are measured according to ASTM F2502-17, which covers bioabsorbable plates and screws for internal fixation. The annealing step also relaxes residual orientation from injection molding, thereby reducing warpage in thin-walled geometries. Annealing above 120 °C or for longer than 12 h risks lactide monomer regeneration and surface discoloration. Because the final device shape determines heat-transfer uniformity, thermal mapping inside the annealing vessel is required for each new cavity geometry. Published data for this specific grade in FDA-cleared load-bearing devices is limited; mechanical equivalence to predicate devices must be established under ASTM F2502-17 rather than inferred from raw-material thermal data.